High serum levels of interleukin-6 in patients with advanced or metastatic colorectal cancer: the effect on the outcome and the response to chemotherapy plus bevacizumab

Surgery Today

Volumn 47, Issue 4, 2017, Pages 483-489

  Hara, Masayasu ^a   Nagasaki, Takaya ^a   Shiga, Kazuyoshi ^a   Takahashi, Hiroki ^a   Takeyama, Hiromitsu ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Bevacizumab; Chemo resistance; Colorectal cancer; Interleukin 6 (IL 6)

Indexed keywords

BEVACIZUMAB; CAPECITABINE PLUS OXALIPLATIN; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 6; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN; ANTINEOPLASTIC AGENT; IL6 PROTEIN, HUMAN; TUMOR MARKER; VASCULOTROPIN A;

ADULT; ADVANCED CANCER; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; NORMAL VALUE; ONCOGENE K RAS; OVERALL SURVIVAL; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; CANCER STAGING; COLORECTAL NEOPLASMS; MIDDLE AGED; MORTALITY; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SECONDARY; SURVIVAL RATE; TIME FACTOR;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84983514201     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-016-1404-7     Document Type: Article

References (25)

1. Hainsworth JD, Spigel DR, Burris HA 3rd, Waterhouse D, Clark BL. Whorf R Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol. 2010;28:2131–6.
2. Wang Y, Deng G, Liu X. Cho WC Monoclonal antibodies in lung cancer. Expert Opin Biol Ther. 2013;13:209–26.
3. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011;29:3968–76.
4. Selvakumaran M, Yao KS, Feldman MD. O’Dwyer PJ Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol. 2008;75:627–38.
5. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M, et al. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res. 2007;67:11244–53.
6. Tural D, Ozturk M, Selcukbiricik F, Yildiz O, Elicin O, Turna H, et al. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer. J BUON. 2013;18:385–90.
7. Middleton K, Jones J, Lwin Z. Coward JI Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol. 2014;89:129–39.
8. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27:3020–6.
9. Saidi A, Hagedorn M, Allain N, Verpelli C, Sala C, Bello L, et al. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer. 2009;125:1054–64.
10. Chalam KV, Grover S, Sambhav K, Balaiya S, Murthy RK. Aqueous interleukin-6 levels are superior to vascular endothelial growth factor in predicting therapeutic response to bevacizumab in age-related macular degeneration. J Ophthalmol. 2014;2014:502174.
11. Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Sato M, et al. Preoperative serum interleukin-6 is a potential prognostic factor for colorectal cancer, including stage II patients. Gastroenterol Res Pract. 2016;2016:9701574.
12. Sakurai T, Kudo M. Signaling pathways governing tumor angiogenesis. Oncology. 2011;81(Suppl 1):24–9.
13. Jurgensmeier JM, Schmoll HJ, Robertson JD, Brooks L, Taboada M, Morgan SR, et al. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer. 2013;108:1316–23.
14. Bruhn MA, Townsend AR, Khoon Lee C, Shivasami A, Price TJ, Wrin J, et al. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. Int J Cancer. 2014;135:731–41.
15. Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, Bernaards C, et al. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res. 2013;19:929–37.
16. Asghar U, Hawkes E, Cunningham D. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer. 2010;9:274–81.
17. Porta C, Paglino C, Imarisio I, Ganini C, Sacchi L, Quaglini S, et al. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology. 2013;84:115–22.
18. Riehle KJ, Campbell JS, McMahan RS, Johnson MM, Beyer RP, Bammler TK, et al. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J Exp Med. 2008;205:91–103.
19. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene. 2002;21:2000–8.
20. Nagasaki T, Hara M, Nakanishi H, Takahashi H, Sato M. Takeyama H Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer. 2014;110:469–78.
21. Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers. 2015;7:2443–58.
22. Nagasaki T, Hara M, Shiga K, Takeyama H. Relationship between inflammation and cancer progression: recent advances in interleukin-6 signaling and its blockage in cancer therapy. Recept Clin Investig. 2014. doi:10.14800/rci.14202.
23. Forger F, Villiger PM. Treatment of rheumatoid arthritis during pregnancy: present and future. Expert Rev Clin Immunol. 2016;27:1–8.
24. Chen X, Wang L, Wang W, Zhao L, Shan B. B7–H4 facilitates proliferation of esophageal squamous cell carcinoma cells through promoting IL-6/STAT3 pathway activation. Cancer Sci. 2016;107:944–54.
25. Stanam A, Love-Homan L, Joseph TS, Espinosa-Cotton M, Simons AL. Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma. Mol Oncol. 2015;9:1371–83.